心脏病综合征和糖尿病:一个邪恶的配对
Ana Belén Méndez Fernández1, Ander Vergara Arana2, Aleix Olivella San Emeterio1
1Department of Cardiology, Hospital Universitario Vall d´Hebron, Barcelona, Spain.
Frontiers in cardiovascular medicine
|May 26, 2023
概括
心脏病综合征 (CRS) 涉及心脏和脏功能障碍,由糖尿病恶化. 像SGLT2抑制剂这样的新药对这些复杂心代谢患者提供了更好的结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏病综合征 (CRS) 描述了心脏和脏的相互关联功能障碍.
- 糖尿病 (DM) 显著增加心力衰竭 (HF) 和慢性病 (CKD) 的风险,这是导致衰竭的主要原因.
- 结合CRS和DM与更高的住院和死亡率有关.
研究的目的:
- 突出管理心脏病综合征和糖尿病患者的挑战.
- 讨论心脏病患者不断变化的治疗环境.
- 强调多学科护理和新药药理学剂的作用.
主要方法:
- 关于心综合征,糖尿病和相关治疗的当前文献的综述.
- 对-葡萄糖共运输体2型 (SGLT2) 抑制剂和葡萄糖样-1受体激活剂 (GLP-1RA) 影响的分析.
- 讨论专业心脏病单元和多学科团队的好处.
主要成果:
- SGLT2抑制剂在2型DM,CKD和HF患者中显示出心血管方面的益处,为CRS提供了新的治疗途径.
- 在DM和心血管疾病患者中,GLP-1RA已经显示出心血管益处,并减少了CKD进展.
- 综合护理模式和新药类正在改善心脏,脏和代谢疾病的管理.
结论:
- 心脏,脏和糖尿病之间的相互作用需要全面的管理方法.
- 新型药物疗法,包括SGLT2抑制剂和GLP-1RA,在治疗心脏病综合征方面取得了重大进展.
- 多学科心单元对于优化整体患者护理和结果至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
472
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
01:22Heart Failure Drugs: Diuretics
432
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
432
01:30Coronary Artery Disease I: Introduction
34
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
34
01:18Chronic Kidney Disease IV: Nursing Management
30
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
30
01:24Chronic Kidney Disease II: Clinical Manifestations
46
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
46
01:29Heart Failure II: Pathophysiology
17
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
17